Gastroparesis Pipeline

DelveInsight’s, “Gastroparesis  - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Gastroparesis  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Gastroparesis: Understanding

Gastroparesis: Overview

Gastroparesis is a chronic condition characterized by delayed gastric emptying without mechanical obstruction, persisting for at least three months. It commonly presents with nausea, vomiting, bloating, early satiety, and abdominal pain, resulting from impaired gastrointestinal motor function involving the nervous system, smooth muscle, pacemaker cells, and pyloric sphincter, alongside immune alterations. Idiopathic causes are most frequent, followed by diabetic, postsurgical, and postinfectious origins, with rising incidence linked to increasing rates of diabetes, obesity, and certain medications. Symptoms often overlap with functional dyspepsia, necessitating diagnostic testing, while management primarily relies on dietary modifications due to limited efficacy and tolerance of medications.

Gastroparesis is identified by delayed gastric emptying in symptomatic patients once other causes like ulcer disease, obstruction, or malignancy are excluded. Symptoms include nausea, vomiting, early satiety, bloating, postprandial fullness, abdominal pain, and weight changes, though these are nonspecific and may overlap with other disorders. To assess severity, tools such as the Gastroparesis Cardinal Symptom Index (GCSI) are used, which evaluates nausea/vomiting, postprandial fullness/early satiety, and bloating, providing standardized grading for both clinical and patient-reported symptom tracking.

Gastroparesis arises from impaired coordination of gastric motor functions that normally enable trituration, mixing, and emptying of food. Normally, peristaltic antral contractions grind solids into particles under 2 mm, which then pass through the pylorus into the duodenum; impaired antral contractions and reduced pyloric relaxation disrupt this process, leading to stasis and sometimes bezoar formation. Neuromuscular regulation involves smooth muscle cells, interstitial cells of Cajal (pacemakers generating slow waves), PDGFRα-positive cells, and the enteric nervous system, with vagal pathways playing a critical role. In gastroparesis, reduced nitric oxide may increase pyloric tone, while localized immune infiltration with macrophages and CD8 T-cells further contributes to dysfunction. Idiopathic and diabetic gastroparesis often feature antral hypomotility, while infiltrative disorders such as systemic sclerosis cause weaker contractions despite normal frequency. Postvagotomy and gastric resections impair gastric accommodation and contractility, and elevated postprandial gastric volume is also linked to delay emptying.

Management of gastroparesis requires a comprehensive approach aimed at correcting nutritional and electrolyte deficiencies, alleviating symptoms, improving gastric emptying, and addressing underlying causes. Dietary modifications are central, with recommendations for small, frequent meals composed of low-fat, low-fiber, and small-particle foods, while avoiding carbonated drinks, alcohol, and tobacco; nutritional supplements or enteral feeding may be required in severe cases. Pharmacologic therapy includes antiemetics (e.g. prochlorperazine) for symptom relief and prokinetics such as metoclopramide, the only FDA-approved drug, though its use is limited by significant side effects. Off-label options include domperidone (restricted in the U.S.), erythromycin, and other agents like 5-HT4 agonists and centrally acting antidepressants. Nonpharmacologic interventions such as gastric electrical stimulation (GES) offer benefit in refractory diabetic or idiopathic cases, though risks include infection and device complications. Surgical or endoscopic measures, such as venting gastrostomy, jejunostomy, pyloroplasty, or intrapyloric botulinum toxin, are less established, with mixed evidence of efficacy. Emerging therapies under investigation include serotonin and neurokinin receptor antagonists, ghrelin agonists, cannabinoids, acupuncture, and novel drug delivery approaches, offering potential future treatment options.

 

"Gastroparesis - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroparesis pipeline landscape is provided which includes the disease overview and Gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroparesis  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Gastroparesis.

 

Gastroparesis Emerging Drugs Chapters

This segment of the Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Gastroparesis Emerging Drugs

• CIN-102: CinDome Pharma, Inc.

Deudomperidone (CIN-102) is a novel chemical entity derived through deuteration and reformulation of domperidone, a widely prescribed first-line therapy for nausea, vomiting, and gastroparesis. Orally administered, it has been specifically designed to modify the pharmacokinetic profile, delivering sustained efficacy while markedly reducing cardiac risk. Clinical trials have consistently shown deudomperidone to be well tolerated, with no sponsor-assessed drug-related adverse events or clinically significant laboratory abnormalities observed. Currently, the drug is in Phase II stage of its development for the treatment of Gastroparesis.

 Further product details are provided in the report……..

 

Gastroparesis: Therapeutic Assessment

This segment of the report provides insights about the different Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Gastroparesis

• There are approx. 6+ key companies which are developing the therapies for Gastroparesis. The companies which have their Gastroparesis drug candidates in the most advanced stage, i.e. Phase II include, CinDome Pharma, Inc.

 

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Gastroparesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Gastroparesis therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroparesis drugs.

 

Gastroparesis Report Insights

• Gastroparesis  Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Gastroparesis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastroparesis drugs?
• How many Gastroparesis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroparesis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroparesis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastroparesis and their status?
• What are the key designations that have been granted to the emerging drugs?